Amneal Pharmaceuticals, Inc. 4

Director J. Kevin Buchi had 34,819 RSUs vest into Class A Common Stock and received a new award of 19,824 RSUs of Amneal Pharmaceuticals, Inc. (AMRX), with no market purchases or sales.

On May 7, 2026, director J. Kevin Buchi converted 34,819 previously granted restricted stock units (RSUs) into an equal number of Amneal Pharmaceuticals, Inc. Class A Common shares in two related transactions: 34,819 shares were acquired in a direct holding and a corresponding 34,819-share movement was recorded involving an indirect trust account, both at a nominal transaction price of $0.00 as these were vesting events rather than open-market trades. Separately, on May 6, 2026, he received a new grant of 19,824 RSUs, each representing a contingent right to one share of Class A Common Stock, pursuant to the company’s director compensation arrangements, with vesting tied to the issuer’s annual meeting schedule and the first anniversary of grant. After these transactions, his direct holdings increased while his indirect trust holdings remained significant, reflecting routine equity-based compensation and vesting rather than discretionary buying or selling. The Form 4 indicates these are non-cash awards and vestings with no sale of shares into the market.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

sec

Accession

0001628280-26-032929

Alert Tier

5